IOSP · XBRL financial data
Innospec financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (IOSP's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 464 | 495* | 500 | 435 | 443 | 467* | 441 | 440 | 442 | 456* | 453 | 491 |
| Cost of goods and services sold | 327 | 339* | 345 | 308 | 319 | 331* | 316 | 317 | 325 | 328* | 330 | 353 |
| Gross profit | 137 | 156* | 156 | 127 | 124 | 136* | 125 | 123 | 117 | 127* | 124 | 138 |
| Research and development | 12 | 9* | 12 | 12 | 11 | 13* | 13 | 14 | 14 | 11* | 13 | 14 |
| Selling, general and administrative | 84 | 102* | 93 | 73 | 67 | 81* | 69 | 75 | 72 | 69* | 79 | 84 |
| Total operating expenses | 95 | 111* | 105 | 86 | 79 | 95* | 83 | 89 | 111 | 81* | 87 | 99 |
| Operating income (loss) | 42 | 45* | 51 | 41 | 46 | 41* | 43 | 34 | 6 | 47* | 37 | 40 |
| Interest expense | — | year only | — | — | — | year only | — | — | — | year only | — | — |
| Other income (expense) | 5 | (1)* | 3 | 1 | (4) | 10* | (1) | (5) | 3 | 2* | 3 | 1 |
| Income tax expense (benefit) | 8 | 8* | 14 | 13 | 11 | (32)* | 12 | 8 | (1) | 3* | 9 | 10 |
| Net income (loss) | — | — | — | — | — | — | 33 | 24 | — | — | 30 | 31 |
| Earnings per share, basic USD per share | 1.58 | — | 1.66 | 1.25 | 1.34 | — | 1.31 | 0.94 | 0.52 | — | 1.23 | 1.25 |
| Earnings per share, diluted USD per share | 1.57 | — | 1.65 | 1.24 | 1.33 | — | 1.31 | 0.94 | 0.52 | — | 1.22 | 1.25 |
| Weighted average shares, basic millions of shares | 25 | 25* | 25 | 25 | 25 | 25* | 25 | 25 | 25 | 25* | 25 | 25 |
| Weighted average shares, diluted millions of shares | 25 | 25* | 25 | 25 | 25 | 25* | 25 | 25 | 25 | 25* | 25 | 25 |
Balance sheet
CSVFiscal quarters (IOSP's year ends in late December)
Cash flows
CSVFiscal quarters (IOSP's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | — | — | — | — | — | — | 33 | 24 | — | — | 30 | 31 |
| Stock-based compensation | 2* | 2* | 2 | 2* | 2* | 2* | 2 | 2* | 1* | 3* | 2 | 2* |
| Depreciation and amortization | 10* | 10* | 10 | 11* | 11* | 11* | 11 | 11* | 12* | 9* | 10 | 10* |
| Net cash from operating activities | 58* | 72* | 81 | 5* | 74* | 26* | 28 | 9* | 39* | 61* | 18 | 7* |
| Net cash from investing activities | (17)* | (56)* | (14) | (15)* | (12)* | (21)* | (16) | (16)* | (24)* | (19)* | (14) | (17)* |
| Share repurchases | 0* | 0* | 0 | 0* | 0* | 0* | 5 | 9* | 11* | 0* | 7 | 6* |
| Dividends paid | 0* | 18* | — | — | 0* | 20* | — | — | 0* | 22* | — | — |
| Net cash from financing activities | 0* | (20)* | 1 | (19)* | 1* | (18)* | (4) | (29)* | (11)* | (21)* | (7) | (30)* |
| Net change in cash | 41* | (4)* | 66 | (30)* | 64* | (15)* | 11 | (33)* | 4* | 22* | (3) | (39)* |
Compare with peers
SIC 2800 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2800 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Innospec | 250 | 491 | 7.2* | 24.6M | — | 10-QJun 30, 2026 |
| Ingevity | 97 | 314 | (14)* | 34.4M | 7.1 quarters | 10-QJun 30, 2026 |
| Chemours | 671 | 1,591 | 158* | 150.5M | — | 10-QJun 30, 2026 |
| Huntsman | 359 | 1,717 | not reported | 175.3M | — | 10-QSep 30, 2026 |
| Ecovyst | 88 | 250 | 34* | 109.5M | — | 10-QJun 30, 2026 |
| Perimeter Solutions | 83 | 214 | (0.7)* | 163.7M | 126.6 quarters | 10-QJun 30, 2026 |
| OLIN | 215 | 1,748 | 110* | 114.0M | — | 10-QSep 30, 2026 |
| Solstice Advanced Materials | 750 | 1,148 | 262* | 158.8M | — | 10-QJun 30, 2026 |
| Balchem | 66 | 291 | 70* | 31.8M | — | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.